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Abstract
Generic drugs have been approved for use by the Food and Drug Administration
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand
name version. Generic drugs constitute approximately two- thirds of all prescriptions
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et
al., 2011). However, concerns about the safety and bioequivalence of the generic versions
of specific drugs are raised regularly (Kesselheim et al., 2010). Despite evidence
supporting bioequivalence, many observational studies have shown an increase in seizure
occurrence with the use of generic drug formulations (Papsdorf et al., 2009; Berg et al.,
viii

2008; for review see Yamada & Welty, 2010). These issues have not slowed the
trend by medical insurance companies to mandate use of generic drugs over brand name
drugs, and commercial and government insurance programs continue to prioritize the use
of generics in most circumstances (Keenum et al., 2012). Although the use of generic
medications can result in substantial savings for the American patient, anecdotal evidence
indicates that beliefs concerning the safety and effectiveness of generic drugs compared
to brand name medication may persist among patient subgroups as well as among
medical practitioners (Figueiras et al., 2010; Ngo et al., 2013). While generic drug
substitution may lead to immediate cost savings, these substitutions may be associated
with additional expenses incurred due to increased adverse events, lack of adherence to
therapy, and to the resulting failure of those therapies (Shin et al. 2014).
The purpose of this study is to examine: 1) the extent to which generic switch is
practiced for privately insured US patients; 2) variations in adherence to AED
medications for patients by brand name and generic AED and switching between the two,
and 3) medical outcomes based on compliance to treatment. We examine factors
associated with the use the antiepileptic brand drug Dilantin® manufactured by Pfizer,
generic Phenytoin, and generic switch in 19-64 year old patients who have private
insurance.

Keywords: Dilantin®, Phenytoin, generic, switch, compliance, epilepsy, seizure
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Chapter 1: Introduction
Background and Need for the Study
Generic drugs have been approved for use by the Food and Drug Administration
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand
name version. Generic drugs constitute approximately two- thirds of all prescriptions
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et
al., 2011). Numerous studies (Andrade, 2015a; Andrade, 2015b; Davis et al., 2015; Jiang
et al., 2015; Krauss et al., 2011) as well as general clinical acceptance and experience
have validated this standard. However, concerns about the safety and bioequivalence of
the generic versions of specific drugs are raised regularly (Kesselheim et al., 2010).
Despite evidence supporting bioequivalence, many observational studies have shown an
increase in seizure occurrence with the use of generic drug formulations in the treatment
of epilepsy (Papsdorf et al., 2009; Berg et al., 2008; for review see Yamada & Welty,
2010). Yet the issues raised about the current bioequivalence standards have not slowed
the trend by medical insurance companies to mandate use of generic drugs over brand
name drugs in order to realize cost savings. Commercial and government insurance
programs have prioritized the use of generics in most circumstances (Keenum et al.,
2012). Additionally, the use of generic medications can result in substantial savings for
the American patient due to the lower cost of generics compared to branded medications.
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However, anecdotal evidence indicates that beliefs concerning the safety and
effectiveness of generic drugs compared to brand name medication may persist among
patient subgroups as well as among medical practitioners (Figueiras et al., 2010; Ngo et
al., 2013). Studies have investigated patients’ perceptions of generics, and researchers
report that although the consumer appreciates the cost savings from generics, some
individuals are unwilling to use them, and medication compliance could be negatively
affected (Kohli & Bueller, 2013, Shin et al., 2014).
In a 2009 study of commercially insured adults (Kohli & Bueller, 2013), 94% of
patients agreed that generics are less expensive than brand name, yet only 37.6% of
respondents would rather take a generic than a brand name medication. In the same
study, researchers identified very different levels of acceptance of generic medications by
individuals based on income and age (Kohli & Bueller, 2013). High-income patients were
more likely than low-income patients to prefer generic medications. Older patients and
more severely ill patients were more likely to report concerns about the safety of generics
than healthy, high-income patients (Kohli & Bueller, 2013). Thus, while generic drug
substitution may lead to immediate cost savings, it is possible that generic substitutions
may be associated with additional expenses incurred due to increased adverse events,
lack of adherence to therapy, and to the resulting failure of those therapies (Shin et al.
2014). This effect may be especially pronounced in subgroups of patients characterized
by factors such as culture, social status, or personal and psychological characteristics.
Indeed, studies continue to show that disadvantaged consumers may be reluctant to use
generic drugs and may distrust generic medications (Keenum et al., 2012).
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This distrust of generic substitutes may be especially dangerous for drugs that are
essential for patient health and functioning. One example is the concern raised over
generic substitution of drugs used for the management of epilepsy (Krauss et al., 2011;
Kesselheim et al., 2010). The management of epilepsy requires anti-epileptic drugs
(AEDs) in approximately 70-80% of patients, and some clinicians have raised concern
that these patients may be at higher risk of non-adherence and seizures when switched
from a brand name drug to generic AEDs (Kesselheim et al., 2010). This issue has raised
such heated debate in the medical community that the FDA was requested by leading
epilepsy organizations to issue a statement opposing mandatory switching from brand
name drugs to generic AEDs. The FDA refused to issue a guidance statement on the
matter, resulting in certain states (e.g. Hawaii, Tennessee) passing their own AED
specific legislation. In these states, informed consent from both the provider and the
patient is required before a generic substitution is permitted (Kesselheim et al., 2010).
However, little is known about the current practice of switching from brand name to
generic switch for AED. Table 1 outlines several organizations across the globe which
have made legislation or strong recommendations regarding the use of generics in the
treatment of epilepsy.
Table 1
Guidelines for generic prescription of AEDs (Atif et al., 2016)
Country

United
States

Organization

Principal recommendations

AAN

The AAN argues the generic substitution of AEDs and
advises to seek consent of attending physician

Epilepsy Foundation

Both physician and patient should give consent and to
be notified upon substitution of AEDs

FDA

According to the FDA, a therapeutically equivalent
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Country

Organization

Principal recommendations
product (either generic or brand) may be expected to
have equivalent clinical effects
The physicians involved in epilepsy treatment are
trained for selection of appropriate AEDs and their
dosages to minimize or eradicate seizures and to avoid
adverse events

American Epilepsy
Society

It is done by utilizing the best available scientific
evidences and clinical expertise
Also, the society contradicts the formulation
substitution of AEDs without obtaining approval from
the physician as well as the patient

England

NICE

Be precautious while generic substitution of AEDs
having complex pharmacokinetics that may cause
larger differences in therapeutic effects upon minor
changes in drug absorption
A switch must be avoided for patients having wellcontrolled seizures

Germany

German chapter of
ILAE

Consider a generic switch towards a lower cost AED
only for the patients having poorly controlled seizures.
It is better to initiate the treatment with a low-cost
AED
The serum drug levels should be monitored closely
while switching and the patient should be informed
about the potential risks
For patients exhibiting partial controlled seizures upon
treatment with a brand AED, it might be appropriate to
switch to a generic product

Italy

Italian chapter of
ILAE

The patient should be informed about the properties
and nature of these products
A switch is not recommended for the patients having
well-controlled seizures

France

LFCE

AEDs belong to a class that may cause problems when
substituted. It is recommended to avoid generic
substitution of AEDs

Poland

Polish Society of
Epileptology

Because of an increased risk of deterioration in
epilepsy patients switching of formulations is
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Country

Organization

Principal recommendations
contraindicated
Pharmacists should not make substitution without
informing the physicians and the physicians are
responsible to make aware the patients of all the
potential and possible risks

Scotland

Scottish
Generic substitution of AEDs should not be made as
Intercollegiate
different available formulations of AEDs are not
Guidelines Network switchable

Sweden

Swedish Medicinal
Products Agency

Netherland

Netherlands Society
The substitution of AEDs is not recommended
of Child Neurology

Switching between formulations may cause a poor
control of seizures

AAN American Academy of Neurology, FDA Food and Drug Administration, NICE
National Institute for Health and Care Excellence, ILAE International League Against
Epilepsy, LFCE Ligue Francaise Contre L’Epilepsie

Background on Epilepsy
Epilepsy is a heterogeneous, chronic and serious brain disorder with multiple
manifestations. An epileptic seizure results from transient abnormal synchronization of
neurons in the brain which disrupts normal patterns of neuronal communication, resulting
in waxing and waning electrical discharges (Moshe et al., 2015). Epilepsy comprises
many seizure types and epilepsy syndromes, some of which are life threatening (Schmidt
& Schachter, 2014), and is defined as two or more unprovoked seizures. By this
definition, epilepsy affects 45 million people worldwide and the incidence is
approximately 26 to 40 per 100,000 person years (French & Pedley, 2008). The annual
economic cost of epilepsy in the US in 2011 was $15.5 billion in direct healthcare
associated costs as well as indirect costs due to employment loss, wage loss or reduction,
and losses in productivity (Epilepsy at a Glance, 2011). Treatment has often been
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empirically based on trial and error, and does not prevent or reverse the pathological
process of the disorder (Schmidt & Schachter, 2014).
Epilepsy is one of many chronic diseases in which medication non-adherence is
problematic. Studies estimate that between 30% and 60% of patients with epilepsy are
non-adherent to their drug regimen, which can lead to higher seizure recurrence and
increased medical resource utilization and costs (Davis et al., 2008).
Treatment of Epilepsy
The American Academy of Neurology, the American Epilepsy Society and the
International League against Epilepsy have issued guidelines for the selection of
pharmacologic therapy in patients with newly diagnosed epilepsy (French & Pedley,
2008)(Table 1). For these diagnosed patients, treatment with an antiepileptic drug is
commonly recommended, especially if further seizures might result in serious morbidity
or mortality (Schmidt & Schachter, 2014). Antiepileptic drugs should fully control
seizures and be well tolerated with no long term safety problems, such as teratogenicity
or hypersensitivity reactions (Schmidt & Schachter, 2014). The introduction of more than
15 antiepileptic drugs since 1980 has provided choice, but selecting the optimum drug,
brand or generic, requires balancing of advantages and limitations to meet the patient's
needs (Schmidt & Schachter, 2014).
Drug Safety
Drug safety is a major public health concern in the United States and both patients
and health care providers must make sound decisions and be well informed of the
potential benefits and harms of available treatment options. The efficacy and safety of
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brand name prescription drugs continues to be examined in multiple randomized clinical
trials conducted during drug development and Phase IV follow-up studies after FDA
approval. Drug safety is the highest priority for patients and health providers, and the
drug side effect profiles are key to many patients’ decision making about taking
prescribed medications (Knapp et al., 2004).
Conventional methods of drug safety surveillance involve literature searches and
individual analysis of reports of adverse events. Currently, the FDA data mines utilizing
tools such as the Multi-item gama poisson shrinker (MGPS) in combination with their
adverse event reporting system database (Ohno-Machado, 2015). In 2007, FDA Public
law no: 110-85 mandated the use of observational data as part of the active drug safety
surveillance system (FDA, 2015). These data sources explore pharmacoepidemiologic
evaluation studies, yet statistical methods for screening observational data to generate
hypothesis about potential drug effects have not been rigorously explored across
mainstream data sources (Schneeweiss & Avorn, 2005).
Problem Statement
Epilepsy is a common neurological problem affecting 1-2% of the U.S.
population, and has significant social and economic consequences, which can be
minimized by optimal seizure control (McAuley et al., 2009). Medical research on
epilepsy has explored the complexity of pharmacotherapy and has revealed intrinsic
consequences from the pharmacokinetic and pharmacodynamic effects of medicating
epileptic patients. Of particular concern is the increase in the number of prescriptions for
patients aged 65 and older (Kohli & Bueller, 2013). Antiepileptic drugs provide
satisfactory control of seizures for most patients with epilepsy, but the decision to start
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drug treatment requires careful risk benefit analysis (Schmidt, 2009). Generic products
are thought to be therapeutically interchangeable with brand name products and represent
a cost effective alternative (Motola & DePonti, 2006). A controversial topic is the generic
substitution of AED drugs, their interchangeability and equivalency to the brand name
version. A growing number of observational studies have compared patients with
epilepsy being treated with brand name AEDs to those patients switched to generics to
determine seizure control and adverse events (Meyer et al., 2013), yet the results of these
studies are conflicting (Yamada &Welty, 2011).
The purpose of this study is to examine: 1) the extent to which generic switch is
practiced for privately insured US patients; 2) variations in adherence to AED
medications for patients by brand name and generic AED; and 3) to assess medical
outcomes of patients on generic or brand name AEDs.
The Importance of the Study for Population Health
Opportunities exist in the pharmaceutical, educational, and health care industries
to assist research and public policy leaders to improve prescribing medication practices
for epilepsy. Previous research has yielded mixed findings as to whether generic drugs
are therapeutically interchangeable with their brand name counterpart. The present study
is intended to contribute to the literature on the current topic of generic and brand
medication switch in patients with epilepsy, as well as to help clarify issues that must be
considered when requiring the use of generic drugs.
This study will investigate the differences in medication compliance between a
generic and a non-generic AED medication, the rate of switching to a generic option
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within this drug classification, and medical care outcomes for these patients using a
large data set that reflects current practice in the US. The results will help inform the
debate about regulations needed to circumscribe the practice of switching between
brand-name and generic drugs for epilepsy. The results described here may also enable
health care professionals to assume proactive roles in the initiation of a prescription
drug reform for a special patient population, such as epilepsy. Furthermore, this
analysis may contribute to the overall body of knowledge about important interactions
between a common approach to cost savings and population health.
This study is both important and timely, as the topic of generic switching has
become politically contentious, with some US states having recently passed AED
specific legislation requiring informed consent from the prescriber and the patient raising
concern about the safety of generic drugs (Kesselheim et al., 2010).
To better inform this issue, we will examine specific factors associated with the
use the antiepileptic brand drug Dilantin® manufactured by Pfizer, comparing
compliance rates for Dilantin® to those for the generic Phenytoin in 19-64 year old
patients who have private insurance. Data from the MarketScan® database for 2013 will
be used to examine switching behavior and medication adherence as measured by
medication possession ratios, as well as medical care use in a one year period.
Hypotheses:
H1: Patients on generic Phenytoin have higher switch rates than patients on Dilantin®
H2: Patients on generic Phenytoin will have lower medication possession ratios over
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a six month period than patients on branded Dilantin®
H3: Patients with lower medication possession ratios will be more likely to have
medical care use indicative of seizure activity.
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Chapter 2: Literature Review
Overview
A literature review was conducted to expand on the background and need for this
study, analyze previous research, and review other study designs. The primary objectives
of the literature review were to explore generic and brand drug interchange in the
treatment of epilepsy, and to inform optimal study design.
Criteria for Selection of Literature
PubMed, Ovid, Scopus, and Google Scholar databases were searched for relevant
articles for inclusion in this literature review. Three types of terminology were used in the
completion of the literature search: (1) terms related to seizure treatment including:
antiepileptic drug, anticonvulsant, Dilantin®, Phenytoin and (2) terms related to drug
equivalency including: bioequivalence, substitution, and (3) the generic articles that had
key words including each of the different search terms utilized were selected based on
inclusion of human data, and published between 2008 and the present.
Significance of Epilepsy
It is estimated that 2 million people in the United States have epilepsy (CDC, 2015)
and a recent report indicates that over 90% of patients with a seizure diagnosis have taken
at least one drug for AED (CDC, 2015). Epilepsy is one of many chronic diseases in
which medication non-adherence is problematic. Studies estimate that between 30% and
60% of patients with epilepsy are non-adherent to their drug regimen, which can lead to
higher seizure recurrence and increased medical resource utilization and costs (Davis et
al., 2008).
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The FDA considers an approved generic product to be interchangeable with its
brand counterpart as long as the mean area under the curve (AUC) and maximum
concentration (C-max) are within 80-125% of the brand product (FDA, 2015). Generic
drugs possess the same active ingredients, dosage form, strength, route of administration
and labeling to meet the FDA’s approval standards without repeating Phase I, II, III
clinical trials conducted by the original manufacturers (Kesselheim & Gagne, 2015). The
FDA also maintains that all approved generic products are bioequivalent to each other,
even though bioequivalence studies comparing generic AEDs are not always undertaken
(Davit et al., 2009). As a result, stakeholders in the neurology community have explored
generic substitution from the brand Dilantin® and have concluded that this practice may
place patients with epilepsy at risk for loss of seizure control. The practice of switching a
name brand medication for a generic one in patients with epilepsy is also discouraged by
the American Epilepsy Society and the American Academy of Neurology (Kinikar et al.,
2012). These organizations suggest that formulary driven generic interchange of AED
medications should be avoided. Various health care payers have employed payment
initiatives to drive down costs by incentivizing providers to increase the percentage of
generic drugs used (Galanter, 2014).
Treatment Compliance
Leading authors in the field, such as Van Paesschen et al. (2008), Shin et al.
(2014), Kesselheim et al. (2010), and Berg et al. (2008) agree that treatment failure of
AED generic substitution can lead to a lack of treatment compliance, breakthrough
seizures, bodily injuries, and job loss as several of the potential risks. The existing
literature describes individual case reports confirming problems with generic AEDs
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including Carbamazepine, Valproate, and Primidone, where some authors note wideranging variability in the bioavailability of these drugs, unlike other classes of chronic
disorder medications (Berg et al., 2008; Kesselheim et al., 2010; Van Paesschen et al.,
2008; Shin et al., 2014). Other factors, such as baseline seizure count and medication
attitude influence the patient’s perception of seizure control, and can affect the patients’
decision making with regard to whether or not to switch to a generic AED medication
(Bautista et al., 2011). Factors which may be involved in altering bioequivalence of
generic drugs compared to brand name versions include low water solubility, narrow
therapeutic window and drug interactions (Sankar et al. 2010). Non-bioequivalence of
generic medications is thought to come primarily from differences in the manufacturing
process, causing variability of the bioavailability of the generic preparation (Patel et al.,
2012).
Additional individual case reports identified in the current review of the literature
have confirmed problems with generic AED’s such as Phenytoin, Carbamazepine,
Valproate, and Primidone. Some authors attribute these problems to reduced
bioavailability of the generic AED (Berg et al., 2008; Kesselheim et al., 2010; Van
Paesschen et al., 2008; Shin et al., 2014). Continued studies attempt to demonstrate and
specify the problems associated with the generic substitution of AED medications, a
matter that is believed to be both underreported and underestimated. Therefore, it is
important for researchers to establish knowledge regarding the level of breakthrough
seizures and or side effects that occur after switching to a generic product (Van
Paesschen et al., 2008). Clinical and observational studies have provided updates to the
body of literature over the years, illustrating that poor treatment compliance and
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consequent failure of AED treatment can be promoted by generic substitution (Berg et
al., 2008). Literature reviews by Kesselheim and colleagues (2010) and Yamada and
Welty (2011) evaluated eight retrospective studies, which generally demonstrated that
substitution of AED’s resulted in higher use of medical services in patients with epilepsy,
with an apparent link between switching and increased incidences of seizure events
associated with generic AED substitution (Hansen et al., 2013). However, individual
study results remain inconclusive and conflicting, and thus additional evaluations of drug
adherence following switching, and medical outcomes associated with generic switching
are warranted.
What is Known About the Issue?
Epilepsy is a common and chronic disorder where lifetime treatment is often
required. According to the latest estimates, about 1.8% of adults aged 18 years or older
have had a diagnosis of epilepsy or seizure disorder (CDC, 2015). Concerns about
medication cost and drug safety have increased, resulting in an increased notoriety
regarding the clinical equivalence of generic drugs (Kesselheim et al, 2010). Helmers and
colleagues (2010) report, in a retrospective analysis of over 33,000 patients, direct health
care costs during periods of generic use versus brand AED medications were significantly
higher. Epilepsy related medical costs were also higher during periods of generic
treatment, representing 28% of all cause cost difference, due to increased utilization of
both hospital and outpatient services (Helmers et al., 2010). As the use of generic antiepileptic drugs increases, the highly debated topic among healthcare professionals
continues to raise concerns, and remains controversial. According to Crawford and
associates (1996), doubts about the safety of generic prescribing for epilepsy arose in
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1968 after reports of Phenytoin intoxication among patients with epilepsy, yet safety
evidence for epilepsy prescribing is still not conclusive. Scientists have shown that a
relatively small decrease in serum concentrations could result in break through seizures
due to the narrow therapeutic range of AED medications (Shin et al., 2014). The FDA
only requires bioequivalence testing for the original product and not of corresponding
generic substitutions (FDA, 2015). Additionally, a positive or negative 20% difference in
bioavailability is permitted when licensing generics compared with branded drugs, a level
that may be acceptable for most drugs (Crawford et al., 1996). However, small changes in
bioavailability of AEDs specifically may result in poorer control of seizures with
potentially serious implications. There may also be a large difference in bioavailability
among the range of generics, especially those generic AED medications that have a
narrow therapeutic index, which in turn may affect clinical outcomes (Shin et al., 2014).
Although a variety of concerns have been raised regarding the FDA requirements for
bioequivalence, the most urgent appears to be clinicians’ belief that an 80-125% range is
too broad for narrow therapeutic range conditions such as epilepsy (Berg et al., 2008).
Consequently, a great deal of research has focused on the unreliability of
interchanging brand name and generic AED medications, which has raised additional
concern about the fact that more generic medications are being used. This increase in the
use of generic medications is thought to be due to either expiry of patent protection, or
because generics drugs are sold at prices below their brand name counterparts, and thus
can contribute to reduced healthcare spending (Kesselheim et al., 2011). Crawford
(2006) reports that formulary committees, health policy makers, and consumer groups
may see the increased use of generic products as an important tool to battle healthcare
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costs, yet the true costs of generic prescribing must also include the cost of additional
hospital and physician visits and cost of treatment failure, which overall could offset the
savings of the generics.
Concern has been noted with regard to the role of the medical legal environment
if adverse consequences arise from generic substitution, particularly when informed
consent is involved (Crawford et al. 2006). The legal responsibility of the occurrence of a
breakthrough seizure is complicated when the patient’s medication has been switched to
another treatment, considered by regulatory authorities to be equivalent, without
informed consent of the patient. Informed consent is a prerequisite to the inclusion in
clinical studies, however not a legal obligation for switching preparations (Crawford et
al., 2006), further complicating the issue of legal responsibility of any adverse effects.
Prescription drug substitution is addressed in state legislatures. Some legislation
will support the use of generics while other bills have been submitted seeking to restrict
substitution of certain classes of drugs, notably antiepileptic drugs and
immunosuppressants (Shaw & Hartman, 2010). There are variations in both existing and
proposed legislation, but in general these bills aim to prohibit a pharmacist from
substituting or interchanging any AED without prior notification and/or signed consent
from the prescriber and patient (Shaw & Hartman, 2010).
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Table 2

Antiepileptic Drug Substitution Legislation
Hawaii The pharmacist shall not substitute an equivalent generic drug for an
AED except with consent of practioner and the patient. Effective 2003
Illinois No pharmacy interchange of an AED without notification and
documented consent of physician and patient. Effective 10/29/07
Tennessee A pharmacist must provide notification to patient before interchange
of AED as well as prescribing physician. Effective 7/1/07
Utah Pharmacist must notify practitioner prior to substitution whether AED is
generic or brand drug. Effective 5/5/08

(Shaw & Hartman, 2010)
The Role of Phenytoin in Treatment of Epilepsy
The treatment of epilepsy has a very broad degree of complexity which can be
complicated by the unreliability of interchanging brand and generic AED medications.
This study reviews Phenytoin, which has been the most widely used generic medication
to treat seizures over the past twenty years, even though a variety of new compounds
have been released (Das et al., 2013). Phenytoin was first synthesized in 1908 at the
University of Kiel in Germany and marketed under the trade name Dilantin® (Das et al.,
2013).
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Effect of Using Generics on Government Spending
In 2007, the congressional budget office (CBO) examined the use of generic
drugs in Medicare’s outpatient prescription drug benefit for senior citizens and people
with disabilities (Part D), using the claims data from Centers for Medicare and Medicaid
Services (CMS) plans for ten million prescriptions. At that time, about 65% of Part D
prescriptions were filled with generics. The CBO’s goal was to analyze how much was
saved as a result of the use of generic drugs, as well as assess the potential for savings
associated with increasing the use of generics. The CBO also examined savings from
generic substitution. Among Part D prescriptions, of those brand drugs that had a generic
version available more than 90% were filled with the generic option (CBO, 2014).
In a separate analysis by the Department of Health and Human Services (Office
of Inspector General) generic drugs were dispensed 88% of the time when available
(OIG, 2007). For Part D, there was a strong financial incentive to encourage the use of
generic drugs, yet there was little data to reflect how the patients felt about the use of
such generic drugs.
Influence of Patient Illness on Perception of Generics and Brand
In addition to the prescribing habits and protocols of healthcare providers, decisions
about the choice of generic or brand name medicines may also be influenced by
patients’ perceptions and beliefs about treatment, side effects, as well as their illness
(Figueiras et al., 2010). The literature suggests that patients develop beliefs about the
necessity of a specific type of medication for maintaining their health status.
Subsequently, beliefs about illness and medicines are interconnected, and may influence
compliance and outcomes (Omojasola et al., 2012). According to Horne and Weinman
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(1999), literature is scarce regarding how patients make decisions concerning their
medications, or about their preferences for one drug or another. However, there is
evidence that levels of knowledge about medicines in general may influence consumer
attitudes and beliefs about medicines for particular illnesses (Horne & Weinman, 1999),
suggesting that perceptions concerning efficacy and safety of generic prescriptions may
depend on the medical condition being treated. Illness and treatment beliefs may also
play a crucial role in patients’ decisions about the choice between generic and brand
medicines (Figuerias et al., 2008). Figuerias (2008) and authors have argued that the
nature of the illness threat is influenced by the illness label and the interpretation of
symptoms.
According to a study conducted by Dohle and Siegrist (2014), the consumers’
perceptions of an illness was the main determinant of satisfaction with generic drug use,
rather than beliefs regarding the equivalence of brand versus generic medicine. Another
study investigated whether consumers were more likely to utilize a generic medication
or a brand prescription for minor or more serious health problems (Figuerias et al.,
2008). The results indicated that patients are less likely to take generic drugs for chronic
and serious conditions like epilepsy, even when they have had positive experiences with
them and believed they were equal in quality to brand name products (Figuerias et al.,
2008). Decisions not to take generics appeared to be driven by a fear of health loss,
which increased with the seriousness of a disorder, rather than the belief that generics
were in general equivalent to brand name drugs (Omojasola et al., 2012). These and
other findings indicate that the consumer’s perception of their illness also influences the
preference for a medicine (Omojasola et al., 2012). Although we can expect that
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preferences for medicines may differ between the general population and those who
experience a condition, we can assume that the perceptions of illness severity as well as
patient beliefs and knowledge about medicines will all have an important roles in
decisions about the use of generic or brand name treatments (Figueiras et al., 2010).
Conceptual Model
A review of the multidisciplinary literature on seizure outcomes following use of
brand versus generic antiepileptic drugs reveals a lack of comprehensive theoretical
framework for understanding these events and their complexities (Berg et al., 2008;
Hansen et al., 2009; Shin et al., 2014). Berg (2008) argues that definitive evidence on the
effects of generic AED medication substitution is lacking, and it is important for
physicians to take more accountability, reporting any cases involving breakthrough
seizures to the FDA directly. Conversely, other experts have pointed out that a 2010
systematic review provided no evidence of loss of seizure control with generic
substitution for many AED medications (Kesselheim et al., 2010). The topic itself is
wrought with confusion, and studies indicate unclear consensus to guide clinicians
(Privitera, 2013). Applying a process of conceptual framework analysis, as shown in
Figure 1, will provide a theoretical framework to shed new light on the feasibility of
implementing sustainable prescribing practices. This study will contribute important
information to the current database on generic switch, and help clarify the issues that
must be considered when prescribing or switching to generic drugs.
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Figure 1: Representation of the conceptual framework developed for interpretation of
proposed hypotheses.
Past Studies
Literature identified in this review suggests that the majority of studies have
primarily relied on retrospective analysis to show increase in breakthrough seizure
occurrence when switching from brand name to generic drug use in the treatment of
epilepsy (Hansen et al., 2009; Kinikar et al., 2012; Shin et al., 2014; Zachry et al., 2009;
Rascati et al., 2009; Labiner et al., 2010). However, several prospective studies have also
found significant increase in pharmacokinetic outcomes affecting bioequivalence (Olling
et al., 1999; Revankar et al., 1999). Several authors have reported an increase in
switchback rates from generic to brand AED medications using claims databases as their
primary source of data (Lelorier et al., 2008).
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A review of selected study designs suggests that the current approaches do not
appear to have become more advanced or sophisticated over the years. Researchers have
primarily applied existing case control designs and either longitudinal, prospective, or
retrospective analysis (Yamada & Welty, 2011). Most trials identified by this search were
short-term evaluations of small populations and were powered to assess differences in
pharmacokinetic parameters rather than clinical outcomes (Kesselheim et al., 2010).
Future studies could potentially improve external validity and generalizability based on
the sampling model. Providing data about the degree of similarity between the various
study groups utilizing different locations, people, and times of day might continue to
frame the ability to generalize findings.
The Next Step in Study Design
Analyses of administrative insurance claims data to assess the prevalence of
generic switches and adherence has been widely used in a variety of chronic disease
studies. The utilization of claims data presents a good opportunity to provide information
regarding patterns of medication dispensing and may be more generalizable than
observational studies in controlled clinical trials (Kinikar et al., 2012).
A limitation of current clinical research is that controlled trials are frequently
comprised of participants that are not randomly selected, and therefore may be atypical of
real world practice settings (Davis et al., 2008). Data may then be viewed as nonrepresentative of the general population, and study design must be augmented in some
way to address this matter. To this end, it is recommended that future studies of
administrative data to assess medication adherence of generic AED medications are
needed to support previous work using trial-based data (Davis et al., 2008).
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It should be further noted that there is also a pressing need for additional studies
to determine whether there is bioequivalence and therapeutic equivalence between the
brand name medication Dilantin® and the generic medication Phenytoin, both of which
are currently available in the market (Jankovic & Ignjatovic Ristic, 2014). Currently, the
FDA (2015) states that there is no adequate data indicating that current testing for generic
medications is faulty, even with drugs that have narrow therapeutic range conditions. It is
unclear if reported problems are due to underreporting, or if there is actually no problem
to report with generic preparation of AED medications (Berg et al., 2008). Some drug
products may have unique structural or functional attributes that necessitate product
specific approaches to therapeutic equivalence determinations (Kesselheim & Gagne,
2015). Tests to demonstrate therapeutic equivalence following generic approval using
product-specific pathways along with active surveillance studies would be useful in
promoting appropriate use of lower cost generic drugs (Kesselheim & Gagne, 2015).
This is a critical issue that warrants further review.
This study provides a unique opportunity to assess the extent of non-adherence
and or generic switch behavior with currently approved generic AED medications within
a managed care environment. There is a potential opportunity to extrapolate the
association between AED medication non-adherence and future healthcare utilization. In
addition, the identification of specific factors associated with the occurrence of increased
seizures and adverse effects when switching from brand name to generic AED
medications will provide insight into the potential ways in which positive healthcare
behaviors may be fostered, and result in decreased utilization of outpatient and hospital
services (Baustisa et al., 2011). This additional information could also aid clinicians and
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health policymakers to better identify instances where prescribing brand AED
medications would improve patient outcomes.
We use a retrospective analysis of archival statistics utilizing data from the
MarketScan® database for 2013, which contains all billing records for approximately
four million covered individuals. It will be used to examine switching behavior and
medication adherence as measured by medication possession ratios in patients with
epilepsy. Selection bias will be controlled through statistical modeling.
Summary
Chapter 2 provided a review of relevant literature. An overview of relevant
material to the research study at hand was presented, and the implementation of a
conceptual model was discussed, along with the necessity for its use. The different study
designs used in research related to this field of study were reviewed, and the issues with
past study designs were discussed. Information was pulled from these studies regarding
the recommended course of action for future study designs. The criteria for the selection
of literature included within this review are presented. Chapter 3 will offer a description
of the methodology to be used in the completion of this study.
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Chapter 3: Methodology
Study Objective
A retrospective cross sectional analysis of administrative data about the utilization
of generic and brand medications in epilepsy and seizure disorder was conducted. Large
health care utilization databases are frequently used in variety of settings to study the use
and outcomes of therapeutics. Their size allows the study of infrequent events, and their
representativeness of routine clinical care makes it possible to study real-world
effectiveness and utilization patterns (Schneeweiss 2005).
This study’s primary objectives are to examine:
1) The extent to which generic switch is practiced for privately insured US
patients; and
2) Variations in adherence to anti-epileptic medications (AEDs) for patients
switched from brand name and generic AEDs.
3) Medical care use for patients on brand name and generic AEDs.
Hypotheses
We hypothesize that:
● H1: Patients on generic Phenytoin will have higher switch rates than patients on
Dilantin®
● H2: Patients on generic Phenytoin will have lower medication possession ratios
over a one year period than patients on branded Dilantin®
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● H3: Patients with lower medication possession ratios will be more likely to have
medical care use indicative of seizure activity
For the purposes of this study, the use of the antiepileptic brand drug Dilantin®
manufactured by Pfizer will be assessed to measure these effects, and the rates of
compliance will be compared for Dilantin® and the generic medication Phenytoin in 1964 year old privately insured patients. Data from the MarketScan® database for 2013,
which contains all billing records for approximately four million covered individuals, will
be used to examine switching behavior and medication adherence as measured by
medication possession ratios.
Data Collection
The Medical University of South Carolina (MUSC) College of Health Professions
(CHP) purchased rights to the use of the Truven Health Analytics MarketScan® database.
The SAS statistical system was used to gather and summarize the data and then present
for analysis to this author.
The blinded dataset lacks personal health information linked to any specific
patient. Due to the data's lack of individual identifiers, the MarketScan® data was
deemed Non-human research by the Medical University of South Carolina Institutional
Review Board.
Data Population
The International Classification of Diseases-9-Clinical Modification (ICD-9-CM)
codes were used to search the Marketscan® National database. Patients with the ICD-9CM diagnosis code: 345.9, 345.0, 345.1, 345.4, 345.5 representing seizure activity served
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as the primary inclusion criteria. The new data set was refined by selecting from patients
who had the following ICD-9-CM codes: 345.9, 345.0, 345.1, 345.4, 345.5. All
information from the SID databases for each patient was carried over to the new
database, respectively. Multiple hospitalizations for the same individual counted as
separate occurrences.
De-identified patient data were included in the analysis if they (1) were prescribed
Phenytoin for seizure disorder, (2) experienced some form of interchange through the use
of at least one generic Phenytoin prescription in 2010, (3) were at least 19 years of age or
older at the time the medication interchange occurred, and (4) had a continuous
membership in their primary insurance plan for six months before and after the
medication interchange. Patients were excluded if they received Phenytoin for
neuropathy or for a pain diagnosis, as opposed to being prescribed the drug for a seizure
diagnosis. The data for the sample was extracted using the following final diagnosis for
any patient in the dataset: ICD-9-CM coded encounter of a seizure disorder: 345, 345.9,
345.0, 345.1, 345.4, 345.5
Description of Variables
The project independent variable was the brand Dilantin® or generic Phenytoin
medication. The first dependent (y) variables are that of medication possession for each
of the following:
1. Generic Phenytoin switch - Yes/No
2. Dilantin® switch- Yes/No
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The dependent variables identified for a medical care use were:
1.

General admission to inpatient hospital (may or may not seizure related)

2.

Hospital inpatient admission due to seizure

3.

Outpatient visit due to seizure

4.

Emergency department (ED) visit due to seizure

Data Set and Statistical Methods
The raw dataset contained exposure and outcome variables for 6681 patients
followed for 1 year. Data collected from patients on generic Phenytoin or brand name
Dilantin® were used to determine which of these patients had higher switch rates,
medication possession ratios, and medical care events. The following statistical analyses
were conducted: summary statistics are reported as numbers and percentages for
categorical variables and medians and ranges for continuous variables. For hypothesis 1,
Chi-square tests were used to assess statistical significance between groups. Logistic
regression was used to calculate odds ratios, confidence intervals and P-values. This
analysis assessed which patient classes had higher switch rates. For hypothesis 2, the
Kruskal- Wallis nonparametric test assessed the difference in average medication
possession ratios for four groups of treatment switched or non-switched patients. This
analysis determined if patients on generic Phenytoin had lower medication possession
ratios than patients on branded Dilantin®, and if switching from one treatment to another
affected medication possession ratios over a one year period.
Groups were defined as follows:
Group 1: Start on Generic, end on Generic
Group 2: Start on Generic, switch to Dilantin®
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Group 3: Start on Dilantin®, switch to Generic
Group 4: Start on Dilantin®, end on Dilantin®

For hypothesis 3, medication possession was the exposure variable and the
analysis assessed whether patients with lower medication possession ratios were more
likely to have medical care use indicative of seizure activity. Specifically, compliance
was defined for a patient with a ratio > 1 and non-compliant had a ratio < 1. Logistic
regression and poisson regression were used to calculate odds ratios and relative risk,
respectively. The outcomes we identified were as mentioned above: inpatient admissions,
epilepsy related inpatient admissions, outpatient visits, and ED visits.
Study Importance
The studies investigating bioequivalence and interchangeability of brand name
and generic anti-convulsant drugs are sparse, and their results are conflicting. Few studies
have investigated change in seizure control after switching from brand name drugs to
generic medications, a central question in the field of research and treatment. Steady state
plasma concentrations of anticonvulsants and their fluctuations are directly linked to
seizure control, so a study that explores therapeutic equivalence of brand name and
generic was needed. This study provides insight into the "switchability" issues of brand
name and generic anticonvulsants. It serves to provide clinicians with useful data to
evaluate and take into consideration when prescribing anticonvulsants to their patients
with epilepsy, and those patients who are being considered for a switch from brand
named to generic anticonvulsants. This study will contribute important information to the
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current knowledge of effects of generic switches, and help clarify issues that must be
considered when requiring or suggesting the use of generic drugs.
Limitations
The key limitation of this study is the utilization of administrative claims data.
Administrative database research creates potential risks that can make the study
uninterpretable or biased (Walraven 2012). Concerns about database studies include data
validity, lack of detailed clinical information, and a limited ability to control confounding
variables (Schneeweiss & Avorn, 2005). While most guidelines for assessing the validity
of observational studies apply to administrative database research, the unique
characteristics of this data source must be accounted for in the study design to avoid
results that are biased or uninterpretable (van Walraven et al., 2012). Minimization of risk
by providing robust description of data and variables utilizing ICD-9-CM codes will be
important. Employing quality criteria to ensure the accuracy of diagnostic and procedural
codes, distinguishing between clinical and statistical significance and analyzing data
properly to explore the influence of population definitions on study outcomes is key to
providing valid and useful results (van Walraven et al., 2012). Physician beliefs and
prescribing ability to treat epilepsy could influence the patient’s outcomes, thus it is
likely that within provider correlation may exist. This effect must be examined using
statistical methods that control for within provider correlation, if needed. The adoption of
evidence based clinical care pathways and increased education evolves from the strength
of the study and the ability to generalize the results. Accuracy of administrative data is
dependent on the accuracy of the physician documentation as well as the skill of the
medical records professional coding the disease (Tu et al., 2014). The term seizure
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disorder and epilepsy can be used with similar frequency, and including both terms to
identify patients with this condition is recommended (Tu et al., 2014). This study is
unadjusted for possible imbalances for demographics.
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Chapter 4: Results
Hypothesis 1
Data were analyzed using statistical software (R®; Vienna, Austria). The total
number of patients identified as having epilepsy or epileptic syndrome, as well as
currently prescribed generic Phenytoin or Dilantin® in the MarketScan® database were
6681. For H1, logistic regression was conducted to examine the difference in switch rates
between patients who started treatment on Phenytoin versus those who started treatment
on Dilantin®. Of the 6681 patients identified, 4704 patients started treatment with
Phenytoin, and 1977 patients began their treatment with Dilantin®. Data show that 6312
of these patients did not switch treatments, while 369 patients had switched, resulting in a
5.5% switch rate in this sample overall. Within the group who started treatment on
Phenytoin, 4566 patients did not switch and 138 patients switched, a switch rate of 2.9%.
The switch rate for the group of patients who started on Dilantin® was 11.7%, where
1746 patients did not switch from Dilantin®, and 231 patients did switch. A Pearson’s
Chi-squared test with Yates’ continuity correction revealed a significant difference in
switch rates between patients who started treatment on Phenytoin compared to those who
started on Dilantin® χ2 (1, N = 507) = 202.60, p < 0.001. Patients who began treatment
on Dilantin® were more likely to switch treatments than those who started their treatment
with Phenytoin. The difference between these rates was statistically significant (OR =
4.38, 95% CI [3.52-5.44], p < 0.001) and can be seen in Figure 2. Additional data from
the analysis can be found in Table 3.

35

Figure 2: Results of logistic regression analysis on medication switch rates among
epilepsy patients who began treatment on generic Phenytoin, compared to those who
began treatment on Dilantin®. The analysis revealed significant differences in switch
rates between the two groups. Chi-square, odds ratio were significant at p < 0.001. CI =
confidence interval.
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Table 3
Logistic regression coefficients of prescription switch rates in epileptic patients
prescribed generic Phenytoin or Dilantin® in 2013
Independent variable Estimate

Std. error z value p-value

Phenytoin

-3.50

0.09

-40.50

p < 0.001

Dilantin®

1.48

0.11

13.28

p < 0.001

χ2

202.60

p < 0.001

OR (95% CI)

4.38 (3.52-5.44)

p < 0.001

df

1

N

507

Hypothesis 2
A (non-parametric) logistic regression was conducted on the data for H2, which
also yielded highly significant results. The overall distribution of the sample can be seen
in Figure 3. For this hypothesis, data from the 6681 identified patients in the
MarketScan® database was used to compute medication possession ratios for each group
of interest (Group 1: Start on Generic, end on Generic; Group 2: Start on Generic, switch
to Dilantin®; Group 3: Start on Dilantin®, switch to Generic; Group 4: Start on
Dilantin®, end on Dilantin®). The median medication possession ratio for the total
sample (N = 6681) was 99.4 (IQR = 79.65-107.80). The numbers of patients in each
group were as follows; Group 1: 4566 patients, Group 2: 138 patients, Group 3: 231
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patients, Group 4: 1746 patients. The analysis showed significant differences in rates of
compliance, as measured by possession ratios, among the groups; Group 1: Mdn = 98.21,
IQR = 76.92-107.20, Group 2: Mdn = 98.41, IQR = 69.45-113.70, Group 3: Mdn =
100.30, IQR = 86.56-111.40, Group 4: Mdn = 101.7, IQR = 86.96-108.30, p <0.001. This
data suggests that patients who start treatment on Dilantin® and stay on Dilantin® are the
most compliant, while those who start on Phenytoin and switch to Dilantin® are the least
compliant. Additionally, Figure 4 shows that both groups who started treatment on
Dilantin® were more compliant than those starting treatment on Phenytoin. As can also
be seen in Figure 4, the greatest variability in medication compliance, as measured by
medication possession ratios, occurred in Group 2 patients who had switched from
generic Phenytoin to Dilantin® (IQR = 69.45-113.70), followed by those patients in
Group 1 who were taking generic Phenytoin only without switching (IQR = 76.92107.20). Alternatively, the least variability in compliance was seen in Groups 4 and 3, the
Dilantin® only group (IQR = 86.96-108.30), and the Dilantin® switched to Phenytoin
group 3 (IQR = 86.56-111.40), respectively. This suggests that patients who began
treatment with Dilantin® overall showed less variability in compliance than those who
started treatment on Phenytoin. Finally, these data also reveal unexpected findings with
regard to outliers. Group 1 and Group 4 had the greatest number of outliers, followed by
Group 3. However, all groups with the exception of Group 4, contained outliers only in
the direction of lesser compliance. Group 4 (treated with Dilantin® only) is the only
group to contain outliers that reached and exceeded the target compliance. This means
that not only were patients in this group the most compliant of all groups, but even the
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outlying patients from this group were uniquely exhibiting 100% compliance with their
medication regime.

Figure 3. Histogram representing the overall distribution of computed medication
possession ratios for the total sample (N = 6681) of epileptic patients prescribed generic
Phenytoin or Dilantin® in 2013. The data is not normally distributed, leading to the use
of non-linear logistic regression analyses. A large number of patients are non-compliant
with their medication taking regime. Frequency refers to the number of patients from the
total sample.
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Figure 4. Box plot representation of compliance rates, as measured by medication
possession ratios, for epilepsy patients in all four groups over one year (2013). Group 1,
Gen/Gen includes patients who started treatment on generic Phenytoin and ended on
generic Phenytoin (no switch from generic Phenytoin); Group 2, Gen/Dil includes
patients who started treatment on generic Phenytoin and ended on Dilantin® (switched
from generic Phenytoin to Dilantin®); Group 3, Dil/Gen included patients who started
treatment with Dilantin® and ended on generic Phenytoin (switched from Dilantin® to
generic Phenytoin); Group 4, Dil/Dil includes patients who started treatment on
Dilantin® and ended on Dilantin® (no switch from Dilantin®). The dashed horizontal
line represents the target value of 100 (representing 100% compliance). Black bars
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indicate the median value for each group. Red boxes represent the extent of the
interquartile range (1st and 3rd interquartile values). Outliers are represented by empty
circles.

Table 4
Logistic regression analysis of medication possession ratios in epileptic patients by
Group in 2013
1st

3rd

Std.

Group

Min.

Quart.

Median Mean Quart.

Max.

1 (n = 4566)

0.00

76.92

98.21

88.12 107.20

148.00 30.26

2 (n = 138)

17.96

69.45

98.41

91.70 113.70

147.10 30.76

3 (n = 231)

0.00

86.56

100.30

96.28 111.40

142.40 23.36

4 (n = 1746)

0.00

86.96

101.70

95.61 108.30

148.00 23.92

Kruskal-Wallis
χ2

73.46

Df

3
p<

p-Value

0.001

N

6681

Dev.
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Hypothesis 3
Dichotomized Variable Analysis
Total Sample
The third hypothesis tested various medical outcomes associated with compliance
as measured by medication possession ratios. Data for the overall sample was initially
dichotomized by “compliance” and “non-compliance”, where patients were coded 0
(compliant) if their medication possession ratio was ≥ 100, and coded 1 (non-compliant)
when their medication possession ratio was < 100, 100 therefore being the target value
indicating 100% compliance. This revealed that from the total sample of 6681 epilepsy
patients prescribed generic Phenytoin or Dilantin®, there were a 3216 compliant and
3465 non-compliant patients. This dichotomization was also confirmed by analyses for
each group (Compliant: Mdn = 108.1, IQR = 103.70-116.40; Non-compliant: Mdn =
80.84, IQR = 56.57-92.44)
Of the 6681 patients in the total sample, data from MarketScan® reported 642
patients requiring in-patient hospital admissions, 173 patients with epilepsy related
admissions, 433 patients having had outpatient visits, and 5832 attending the emergency
department (ED).
The mean number of ED visits was similar among compliant and non-compliant
patients, M = 1.9 and M = 2.15, respectively. However, the range of ED visits showed
variability, with a greater range in the number of ED visits for non-compliant (range =
0.00-37.00) patients than for compliant patients (range = 0.00-19.00). Over a one year
period, we observed on average a range of 0-19 visits for the compliant and 0-37 visits
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for the non-compliant patients with an overall average of approximately two emergency
room visits for both groups with a slight increase in the non-compliant group.
In-Patient Visits by Compliance
Logistic regression analyses and Pearson’s Chi-squared tests were used to assess
the dichotomized variable data. Data from the MarketScan® database for 2013 showed
that 233 of the 3216 compliant patients required in-patient hospital admissions, compared
to 409 of the 3465 non-compliant patients. These values result in a 7.25% admission rate
for compliant patients, and an 11.80% admission rate for non-compliant epilepsy patients,
a difference that was statistically significant, χ2 (1, N = 442) = 39.38, p < 0.001. Logistic
regression showed that non-compliant patients were 71% more likely to require in-patient
services than compliant patients, OR = 1.71, 95% CI (1.45-2.02), p < 0.001. These results
and additional logistic regression coefficient values are presented in Figure 5 and Table 5.
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Figure 5. In-patient admission rates for compliant and non-compliant epileptic patients,
according to medication possession ratios. These data were statistically significant, p <
0.001.
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Table 5
Logistic regression coefficients of inpatient visits in compliant and non-compliant
epileptic patients prescribed generic Phenytoin or Dilantin® in 2013
Group

Estimate Std. Error z value p-Value

Compliant

-2.55

Non-compliant 0.54

0.07

-37.48

p < 0.001

0.09

6.26

p < 0.001

Epilepsy Related Hospital Admissions by Compliance
Data was also collected from the MarketScan® database regarding the number of
epilepsy related hospital admissions for compliant and non-compliant epileptic patients
prescribed Phenytoin or Dilantin® in 2013. These data showed that 58 compliant
epileptic patients had epilepsy related hospital admissions during the one year period,
while 115 non-compliant patients were admitted for epilepsy related reasons during the
same year. The admission rates for compliant vs. non-compliant patients were 1.80% and
3.32%, respectively. This difference was statistically significant, χ2 (1, N = 173) = 14.59,
p < 0.001. As is shown in Figure 6, non-compliant patients were 87% more likely to have
had an epilepsy related hospital admission than compliant patients, OR = 1.87, 95% CI
(1.36-2.57), p < 0.001. Additional data from this analysis is also provided in Table 6.
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Figure 6. Epilepsy related hospital admission rates for compliant and non-compliant
patients, according to medication possession ratios. These data were statistically
significant, p < 0.001.
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Table 6
Logistic regression coefficients for epilepsy related hospital admissions in compliant and
non-compliant epileptic patients prescribed generic Phenytoin or Dilantin® in 2013
Group

Estimate Std. Error z value p-Value

Compliant

-3.99

Non-compliant 0.63

0.13

-30.17

p < 0.001

0.16

3.84

p < 0.001

Outpatient Visits by Compliance
Poisson regression was used to analyze the data on outpatient and ED visit data
described below. Data on the number of outpatient visits in 2013 showed 188 episodes of
outpatient visits for compliant epilepsy patients as a group. Non-compliant patient data
revealed that 439 episodes of outpatient visits were required in this group. Data also
revealed that, for compliant patients, the incidence rate of outpatient visits was 58 per
1000 person years; for the non-compliant patients, the incidence rate of outpatient visits
was 127 per 1000 person years (RR = 2.17, 95% CI [1.83-2.57], p < 0.001). This data
suggests that if 1000 compliant patients were followed for one year, there would be a
total of 58 outpatient visits within that year. Alternatively, for 1000 non-compliant
patients, the total number of outpatient visits would equal 127 in one year. This also
suggests that non-compliant patients have greater than twice the risk of requiring
outpatient services than do compliant patients. These differences, shown in Figure 7,
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were statistically significant. Poisson regression coefficients are shown in Table 7.

Figure 7. Incidence rates of outpatient visits for compliant and non-compliant epileptic
patients prescribed generic Phenytoin or Dilantin® in 2013
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Table 7
Poisson regression coefficients for outpatient visit incidence rates in compliant and noncompliant epileptic patients prescribed generic Phenytoin or Dilantin® in 2013
Group

Estimate Std. Error z value p-Value

Compliant

-2.84

Non-compliant 0.77

0.07

-38.93

p < 0.001

0.09

8.87

p < 0.001

Emergency Department Visits by Compliance
The number of ED visits in 2013 for compliant and non-compliant epilepsy
patients were alarmingly high. Compliant patients exhibited 6110 ED visits overall as a
group, while non-compliant patients attended the ED 7440 times as a group within this
one year period. The incidence rates of ED visits for compliant and non-compliant
patients were 1900 and 2147 per 1000 person years, respectively (RR = 1.13, 95% CI
[1.09-1.17], p < 0.001). This data, represented in Figure 8, also suggests that noncompliant patients have a 13% greater risk of attending the ED than do compliant
patients. These results were also statistically significant, and corresponding Poisson
regression coefficients are shown in Table 8.
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Figure 8. Incidence rates of emergency department visits for compliant and noncompliant epileptic patients prescribed generic Phenytoin or Dilantin® in 2013
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Table 8
Poisson regression coefficients for emergency department visit incidence rates in
compliant and non-compliant epileptic patients prescribed generic Phenytoin or
Dilantin® in 2013
Group

Estimate Std. Error z value p-Value

Compliant

0.64

0.012

50/17

p < 0.001

Non-compliant 0.12

0.017

7.09

p < 0.001

Continuous Variable Analyses
In-patient Visits
Logistic regression analyses were used to assess the continuous variable data for
medication possession from the MarketScan® database for 2013. These analyses revealed
that a 1% positive change in compliance resulted in a statistically significant 1% decrease
in the number of in-patient hospital admissions, OR = 0.99, 95% CI (0.98-0.99), p <
0.001. Additionally, a 10% positive change in compliance corresponded to a 12%
decrease in in-patient hospitalization which was also statistically significant, OR = 0.88,
95% CI (0.86-0.90), p < 0.001.
Epilepsy Related Hospital Admissions
Analyses of the continuous variable medication possession with regard to epilepsy
related hospital admissions also showed statistically significant results. A 1% positive
change in compliance resulted in a 2% decrease in epilepsy related hospital admissions,
OR = 0.98, 95% CI (0.98-0.98), p < 0.001. A 10% positive change in compliance was
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related to a 16% decrease in epilepsy related admissions, OR = 0.84, 95% CI (0.81-0.88),
p < 0.001.
Outpatient Visits
Continuous data on outpatient visits indicated that a 1% positive change in
compliance resulted in a statistically significant 1% decrease in the number of outpatient
visits (OR = 0.99, 95% CI [0.98-0.99], p < 0.001), while a 10% positive change in
compliance resulted in a 13% decrease in outpatient visits which was also statistically
significant (OR = 0.87, 95% CI [0.85-0.89], p < 0.001).
Emergency Department Visits
Logistic regression conducted on the data regarding the number of ED visits in
epilepsy patients revealed that a 1% positive change in compliance corresponded to a less
than 1% decrease in the number of ED visits, yet this change was statistically significant,
OR = 1.00, 95% CI (1.00-1.00), p < 0.001. A 10% positive change in compliance resulted
in a statistically significant 3% decrease in ED visits, OR = 0.97, 95% CI (0.96-0.97), p <
0.001. These data, despite their significance, suggest that ED visits may be the least
affected by increased compliance.
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Chapter 5: Discussion
Substantial concerns continue to be expressed about potential problems arising
from switching epileptic patients between generic and brand AED drugs. This study was
designed to provide an assessment of brand name Dilantin® and generic Phenytoin,
comparing switch rates, compliance, and seizure related outcomes, as there is growing
concern about the efficacy and safety of generic AED’s (Haskins et al., 2005). Changing
health policy and managed care practices focus on cost containment and may encourage
the use of generics because they are less expensive than their branded counterparts. What
may be greatly underestimated are the additional unexpected costs associated with
switching drugs which can cause both an increase in adverse events and increased
medical use, such as hospitalization and emergency room visits.
Results from this large managed care database demonstrated that patients treated
with Phenytoin had a switch rate of 2.9%, while those patients who started treatment on
Dilantin® showed a switch rate of 11.7%. These initial results appear to support the
body of evidence suggesting that patients who begin treatment on a branded AED (i.e.
Dilantin®) are more likely to switch treatment to a generic. However, an unexpected
finding in our study suggests that those who start on Phenytoin and switch to Dilantin®
are the least compliant compared to other groups in our analyses, as measured by
medication possession ratios. Study investigators initially hypothesized that switches
from generic to brand name Dilantin® would prove better compliance outcomes, yet this
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switch showed the opposite effect and is inconsistent with previous studies conducted in
this area. The greatest rates of compliance were evident in the Dilantin® treated patients
who experienced no switch, and therefore remained on the brand name drug during our
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one year review period. In a recent study, Gagne (2015) showed differing results
with regard to brand/generic interchange, and reported confirmation that generics were
more effective than their brand counterparts. Gagne (2015) provided opposing evidence
that adherence was better for generic AED’s than their branded versions, and better
medication adherence was associated with better patient outcomes.
In the present study, a confirmed relationship between brand or generic AED’s
and compliance, inpatient hospital use, outpatient services, and ED visits was established.
Non-compliant patients were 71% more likely to require in-patient services than
compliant patients, hadgreater than twice the risk of requiring outpatient services than
compliant patients, and were at a 13% greater risk for attending the ED than compliant
patients. These results are in line with previous research such as observational studies by
Zachry et al. 2009, which provide further evidence that AED substitution may increase
use of health care services (hospitalization, ED) and strengthen the association between
switching and adverse outcomes.
Equally important is the attention given to the complexity of pharmacokinetics
between brand and generic AED’s. This influence has proven to be critical to the
implication of AED switching. In 2011, a systematic review of the current evidence on
generic substitution of AEDs was conducted by Yamada and Welty (2011), including a
retrospective and prospective controlled study analysis of generic substitution of AEDs.
The authors found that the majority of past retrospective studies had indicated that
generic AED substitution resulted in higher use of medical services in patients with
epilepsy. Similarly, our study also suggests that switching to generic may be associated
with increased rates of health services utilization and lower medication possession ratios.
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It is important to ensure that patients, pharmacists, prescribers and policy decision makers
are aware of the potential risks of AED switching.
Although the present study had some limitations, our analyses support the
existence of viable concerns and challenges associated with AED switching, for both
patients and health care providers. Until formal guidelines are administered by regulatory
authorities, many epilepsy patients will continue to experience the negative effects of
AED switching. It is clear from our literature review and previously conducted research
that many physicians are concerned about the efficacy and safety associated with
unhampered substitution of generic AEDs, but may inaccurately underestimate how often
generic substitution occurs (Wilner, 2002). Policies that include mandatory substitution
or substitution without informed consent to both patient and provider are clearly
passionate topics and warrant further discussion (Maliepaard et al., 2009). Strong
recommendations regarding generic substitution from The Epilepsy Society and The
American Academy of Neurology as well as other advocacy and medical authorities
detail anecdotal evidence as well as clinical concerns regarding generic substitution.
Several states have issued laws regarding generic substitution, while other states are
considering implementation of similar legislation (Meyer et al., 2013). These groups aim
to scrutinize the need for continued robust studies to evaluate generic AED substitution,
and to directly examine the clinical effects of brand to generic substitution in controlled
trials. Supplementing the existing body of knowledge, The Agency for Healthcare
Research and Quality conducted a comparative effectiveness review in December 2011
which evaluated the effectiveness and safety of AEDs in patients with epilepsy. The
review states that patients who initiate treatment with and AED have no substantive
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differences in benefits or harms associated with the use of generics versus brand name
products (Talati et al., 2011). The review also acknowledges that switching from a brand
name AED to a generic AED may increase health care utilization, but recognizes that
“this is based on controlled observational study data, which has inherent limitations
substantially reducing the strength of evidence” (Talati et al., 2011).
Study Considerations and Recommendations
The results of this study provide additional substance and contributory evidence
regarding epilepsy treatment, switching, and associated medical events, yet has its
limitations. The first major limitation was the use of observational data from a managed
care database, and not utilizing a randomized controlled trial design which might have
included additional patient data such as disease characteristics, seizure frequency, disease
duration or patients identified on multiple AED’s. Our research falls short of specifically
identifying whether generic AED’s directly affect the risk of breakthrough seizures,
however does include important results regarding compliance and medical care use. This
study reinforces evidence showing that when an AED formulation switch occurs,
additional patient monitoring is necessary and patients should be considered individually
regarding the appropriateness for changes in treatment formulation. There remains
important considerations when substituting AED’s as compared to other chronic or acute
medications that need to be underscored. It is clear that further clinical studies are needed
to determine outcomes or possible pitfalls of generic substitution to guide treatment
decisions. Fortunately, there are a growing number of observational studies comparing
outcomes of patients with epilepsy being treated with brand name AEDs or switched to
generic to determine if there are differences in seizure control or seizure-related adverse
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events. Unfortunately, however, the results of these studies are conflicting, with some
showing an increased risk of seizures and medical outcomes when generic AED products
were switched with brand name products (Zachary et al., 2009), and other studies
showing no difference in seizure control (Gagne et al., 2015). More prospective studies
analyzing the pharmacokinetics of brand to generic substitution are needed to assess the
true variability of generic products. It is important to ensure that every patient with
epilepsy is receiving the best health care possible, prescribers and policy makers should
be aware of the current state of disease management including prescribing patterns of
generic AEDs. Our observational data suggest that brand to generic switching may be
associated with increased rates of health services utilization which could increase
national healthcare costs. When any medication change occurs, physicians should
consider intense monitoring of these patients in the absence of conclusive data that
challenge the utilization of generic substitution as there is little evidence to conclude
discontinued use of generic AED’s (Kesselheim et al., 2010). Based on the current
knowledge and attitudes toward generic AED formulations, we conclude that both
patients and physicians need to advocate for education and policy that would help better
inform and enrich the medical community.
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Objective: The purpose of this study is to examine: 1) the extent to which treatment
switch is practiced for privately insured US patients; 2) variations in adherence to antiepileptic drugs (AED) by brand name and generic AED switching, and 3) medical
outcomes based on compliance to treatment.
Methods: A retrospective cross sectional analysis was conducted. Data were included in
analyses if patients (1) were prescribed phenytoin or Dilantin® for seizure disorder, (2)
experienced interchange through the use of at least one generic phenytoin prescription,
(3) were at least 19 years of age or older at the time of medication interchange, and (4)
had a continuous membership in their primary insurance plan for six months before and
after medication interchange. Analyses assessed which patient classes had higher switch
rates, medication possession ratios and medical care events.
Results: A higher switch rate was apparent for patients who started on Dilantin® over
patients who started treatment on phenytoin, p < 0.001, and significant differences in
rates of compliance were apparent. Non-compliant patients were 71% more likely to
require in-patient services than compliant patients, p < 0.001, and 87% more likely to
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have had an epilepsy related hospital admission, p < 0.001. The incidence rate of
outpatient visits was 58 per 1000 person years for compliant patients; for the noncompliant patients, the incidence rate of outpatient visits was 127 per 1000 person years,
p < 0.001. Non-compliant patients have a significant 13% greater risk of attending the ED
than compliant patients.
Significance: It is important to ensure that patients, pharmacists, prescribers and policy
decision makers are aware of the potential risks of AED switching. When medication
change occurs physicians should consider intense monitoring of these patients. We
conclude that both patients and physicians need to advocate for education and policy
related to AED switching.
Key Points:
•

Little is known about the current practice of switching from brand name to
generic for anti-epileptic drugs

•

Higher switch rates occur for epileptic patients initially prescribed brand name
drugs than those on generic drugs

•

Significant differences in rates of compliance occur based on whether patients are
taking brand name or generic treatments

•

Non-compliant patients were 71% more likely to require in-patient services than
compliant patients, and 87% more likely to have had an epilepsy related hospital
admission

•

Non-compliant patients have a significant 13% greater risk of utilizing the ED
than compliant patients.
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•

It is important to ensure that patients, prescribers, and policy decision makers are
aware of the potential risks of AED switching

Introduction
Generic drugs have been approved for use by the Food and Drug Administration
(FDA) since 1984 on the basis of demonstrated bioequivalence as compared to the brand
name version. Generic drugs constitute approximately two- thirds of all prescriptions
dispensed in the US and account for <20% of total pharmaceutical expenditure (Patel et
al., 2011). However, concerns about the safety and bioequivalence of the generic versions
of specific drugs are raised regularly (Kesselheim et al, 2015). Despite evidence
supporting bioequivalence, many observational studies have shown an increase in seizure
occurrence with the use of generic drug formulations (Papsdorf et al., 2009; Berg et al.,
2008; Yamada & Welty, 2010). These issues have not slowed the trend by medical
insurance companies to mandate use of generic drugs over brand name drugs, and
commercial and government insurance programs continue to prioritize the use of generics
in most circumstances (Keenum et al., 2012). Although the use of generic medications
can result in substantial savings for the patient, anecdotal evidence indicates that beliefs
concerning the safety and effectiveness of generic drugs compared to brand name
medication may persist among patient subgroups as well as among medical practitioners
(Figueiras et al., 2010; Ngo et al., 2013). Studies investigating patient perceptions of
generics show that although the consumer appreciates the cost savings from generics,
some are unwilling to use them, and medication compliance could be negatively affected
(Kohli & Bueller, 2013, Shin et al., 2014). For example, in a study of commercially
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insured adults, 94% of patients agreed that generics are less expensive than brand name,
yet only 37.6% of respondents would rather take a generic than a brand name medication
(Kohli et.al, 2013). This effect may be especially pronounced in subgroups of patients
characterized by factors such as culture, social status, or personal and psychological
characteristics, as studies also show that disadvantaged consumers may be reluctant to
use generic drugs and may distrust generic medications (Keenum et. al, 2012).
While generic drug substitution may lead to immediate cost savings, these
substitutions may be associated with additional expenses incurred due to increased
adverse events, lack of adherence to therapy, and to the resulting failure of those
therapies (Shin, 2014). Little is known about the current practice of switching from brand
name to generic (G-switch) for anti-epileptic drugs (AED).
Epilepsy is one of many chronic diseases in which medication non-adherence is
problematic. Studies estimate that between 30% and 60% of patients with epilepsy are
non-adherent to their drug regimen, which can lead to higher seizure recurrence and
increased medical resource utilization and costs (Davis, 2008).
Generic products are thought to be therapeutically interchangeable with brand
name products and represent a cost effective alternative (Motola, 2006). A controversial
topic is the generic substitution of AED drugs, their interchangeability and equivalency to
the brand name version. A growing number of observational studies have compared
patients with epilepsy being treated with brand name AEDs to those patients switched to
generics to determine seizure control and adverse events, (Meyer, 2013) yet the results of
these studies are conflicting (Yamada, 2011).
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The purpose of this study is to examine: 1) the extent to which G-switch is
practiced for privately insured US patients; 2) variations in adherence to AED
medications for patients by brand name and generic AED and switching between the two,
and 3) medical outcomes based on compliance to treatment. We examine factors
associated with the use the antiepileptic brand drug Dilantin® manufactured by Pfizer,
generic phenytoin, and generic switch in 19-64 year old patients who have private
insurance.
Methods
Data from the 2013 MarketScan® database was used to examine switching
behavior and medication adherence as measured by medication possession ratios. A
retrospective cross sectional analysis of 2013 administrative data from patients covered
by commercial health insurance in the United States was conducted. The MarketScan®
database was used in this setting to study the use and outcomes of therapeutics. Their size
allows the study of infrequent events, and their representativeness of routine clinical care
makes it possible to study real-world effectiveness and utilization patterns
(Schneeweiss, 2005).
For the purposes of this study, data from the MarketScan® database calendar year
2013, containing all billing records for approximately four million covered individuals,
were utilized. Eligible patients were identified according to International Classification of
Diseases-9-Clinical Modification (ICD-9-CM) epilepsy diagnosis, as well as treatment by
a medical professional. ICD-9-CM diagnosis codes 345.9, 345.0, 345.1, 345.4, 345.5
representing seizure activity served as the primary inclusion criteria. De-identified patient
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data were included in analyses if patients 1) were prescribed phenytoin or Dilantin® for
seizure disorder, 2) experienced some form of interchange through the use of at least one
generic phenytoin prescription in 2010, 3) were at least 19 years of age or older at the
time the medication interchange occurred, and 4) had a continuous membership in their
primary insurance plan for six months before and after the medication interchange.
Patients were excluded if they received phenytoin for neuropathy or for a pain diagnosis,
as opposed to being prescribed the drug for a seizure diagnosis. Patients who were not
treated for seizure disorder with a primary care physician were not considered for
inclusion within the sample. All information from the original databases for each patient
was carried over to the new database. Multiple hospitalizations for the same individual
counted as separate occurrences. The raw dataset contained exposure and outcome
variables for 6681 patients followed for one year. Summary statistics are reported as
numbers and percentages for categorical variables, and medians and ranges for
continuous variables. A Chi-square test was used to assess statistical significance between
groups. Logistic regression was used to examine the relationship between independent
variable Dilantin and generic phenytoin and dependent variables hospital inpatient
admission due to seizure, general hospital inpatient, outpatient visit due to seizure, and
emergency department visit due to seizure. This analysis assessed which patient classes
had higher switch rates. The Kruskal-Wallis nonparametric test assessed the difference in
average medication possession ratios for 4 groups. Groups were defined as follows:
Group 1, Start on Generic, end on Generic; Group 2, Start on Generic, switch to
Dilantin®; Group 3, Start on Dilantin®, switch to Generic; Group 4, Start on Dilantin®,
end on Dilantin®. This analysis determined if patients on generic phenytoin had lower
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medication possession ratios than patients on branded Dilantin® over a one year period.
In analyses of health outcomes, medication possession was the exposure variable and the
analyses assessed whether patients with lower medication possession ratios were more
likely to have medical care use indicative of seizure activity. Specifically, compliance
with medication was defined for a patient with a ratio > 1 and non-compliant had a ratio
< 1. Logistic regression and poisson regression were used to calculate odds ratios and
relative risk, respectively. Compliance for this study, obtained from medication
possession rates, was used to analyze patients on generic phenytoin or Dilantin® to
determine if these patients had higher switch rates, medication possession ratios and
medical care events. The medical care event outcomes identified were: total inpatient
admissions, epilepsy related inpatient admissions, outpatient visits, and emergency
department (ED) visits.
All analyses were performed using R statistical software (Vienna, Austria), and
statistical significance was determined at the 0.05 level. The SAS statistical system was
used to gather and summarize the data.

Results
Of the 6681 patients identified, 4704 patients started treatment with phenytoin,
and 1977 patients began their treatment with Dilantin®. Data show that 6312 of these
patients did not switch treatments, while 369 patients had switched, resulting in a 5.5%
switch rate in this sample overall. Within the group who started treatment on phenytoin,
4566 patients did not switch and 138 patients switched, a switch rate of 2.9%. In the
group of patients who started on Dilantin®, 1746 patients did not switch from Dilantin®,

65

and 231 patients did switch, resulting in a switch rate of 11.7%. This revealed a
significant difference in switch rates between patients who started treatment on phenytoin
compared to those who started on Dilantin® χ2 (1, N = 507) = 202.60, p < 0.001. Patients
who began treatment on Dilantin® were more likely to switch treatments than those who
started their treatment with phenytoin. The difference between these rates was
statistically significant (OR = 4.38, 95% CI [3.52-5.44], p < 0.001) as shown in Figure 1.

Figure 1: Results of logistic regression analysis on medication switch rates among
epilepsy patients who began treatment on generic phenytoin, compared to those who
began treatment on Dilantin®. Chi-square, odds ratio were significant at p < 0.001. CI =
confidence interval.
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Data from the 6681 identified patients in the MarketScan® database was used to
compute medication possession ratios for each group of interest (Group 1: Start on
Generic, end on Generic; Group 2: Start on Generic, switch to Dilantin®; Group 3: Start
on Dilantin®, switch to Generic; Group 4: Start on Dilantin®, end on Dilantin®). The
median medication possession ratio for the total sample (N = 6681) was 99.4 (IQR =
79.65-107.80). The numbers of patients in each group were as follows; Group 1: 4566
patients, Group 2: 138 patients, Group 3: 231 patients, Group 4: 1746 patients. Analysis
showed significant differences in rates of compliance, as measured by possession ratios,
among the groups (Group 1: Mdn = 98.21, IQR = 76.92-107.20, Group 2: Mdn = 98.41,
IQR = 69.45-113.70, Group 3: Mdn = 100.30, IQR = 86.56-111.40, Group 4: Mdn =
101.7, IQR = 86.96-108.30, p <0.001).
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Figure 2. Box plot representation of compliance rates, as measured by medication
possession ratios, for epilepsy patients in all 4 groups over one year (2013). Group 1,
Gen/Gen includes patients who started treatment on generic phenytoin and ended on
phenytoin (no switch from generic phenytoin); Group 2, Gen/Dil includes patients who
started treatment on generic phenytoin and ended on Dilantin® (switched from generic
phenytoin to Dilantin®); Group 3, Dil/Gen included patients who started treatment with
Dilantin® and ended on generic phenytoin (switched from Dilantin® to generic
phenytoin); Group 4, Dil/Dil includes patients who started treatment on Dilantin® and
ended on Dilantin® (no switch from Dilantin®). The dashed horizontal line represents
the target value of 100 (representing 100% compliance). Black bars indicate the median
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value for each group. Red boxes represent the extent of the interquartile range (1st and 3rd
interquartile values). Outliers are represented by empty circles.
Data regarding medical outcomes associated with compliance as measured by
medication possession ratios was initially dichotomized by “compliance” and “noncompliance”. This dichotomization of the data revealed that from the total sample of
patients prescribed generic phenytoin or Dilantin®, 3216 were compliant and 3465 were
non-compliant.
Data from MarketScan® also showed 642 patients requiring in-patient hospital
admissions, 173 patients with epilepsy related admissions, 433 patients having had
outpatient visits, and 5832 attending the emergency department (ED).
The mean number of ED visits was similar among compliant and non-compliant
patients, M = 1.9 and M = 2.15, respectively. However, the range of ED visits showed
variability, with a greater range in the number of ED visits for non-compliant (range =
0.00-37.00) patients than for compliant patients (range = 0.00-19.00).
Analyses showed that 233 of the 3216 compliant patients required in-patient
hospital admissions, compared to 409 of the 3465 non-compliant patients. These values
result in a 7.25% admission rate for compliant patients, and an 11.80% admission rate for
non-compliant epilepsy patients, a difference that was statistically significant, χ2 (1, N =
442) = 39.38, p < 0.001. Non-compliant patients were 71% more likely to require inpatient services than compliant patients, OR = 1.71, 95% CI (1.45-2.02), p < 0.001.
These results are presented in Figure 3.
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Figure 3. In-patient admission rates for compliant and non-compliant epileptic patients,
according to medication possession ratios. These data were statistically significant, p <
0.001.
Data regarding the number of epilepsy related hospital admissions for compliant
and non-compliant epileptic patients showed that 58 compliant epileptic patients had
epilepsy related hospital admissions during the one year period, while 115 non-compliant
patients were admitted for epilepsy related reasons during the same year. The admission
rates for compliant vs. non-compliant patients were 1.80% and 3.32%, respectively. This
difference was statistically significant, χ2 (1, N = 173) = 14.59, p < 0.001. As is shown in
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Figure 4, non-compliant patients were 87% more likely to have had an epilepsy related
hospital admission than compliant patients, OR = 1.87, 95% CI (1.36-2.57), p < 0.001.

Figure 4. Epilepsy related hospital admission rates for compliant and non-compliant
patients, according to medication possession ratios. These data were statistically
significant, p < 0.001.
Compliant patients experienced 188 outpatient visits overall, while non-compliant
patients experienced 439 outpatient visits. Data also revealed that, for compliant patients,
the incidence rate of outpatient visits was 58 per 1000 person years; for the noncompliant patients, the incidence rate of outpatient visits was 127 per 1000 person years
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(RR = 2.17, 95% CI [1.83-2.57], p < 0.001). These differences, shown in Figure 5, were
statistically significant.

Figure 5. Incidence rates of outpatient visits for compliant and non-compliant epileptic
patients prescribed generic phenytoin or Dilantin® in 2013
Compliant patients exhibited 6110 ED visits overall as a group, while noncompliant patients attended the ED 7440 times as a group within this one year period.
The incidence rates of ED visits for compliant and non-compliant patients were 1900 and
2147 per 1000 person years, respectively (RR = 1.13, 95% CI [1.09-1.17], p < 0.001).
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This data, represented in Figure 6, also suggests that non-compliant patients have a
significant 13% greater risk of attending the ED than do compliant patients.

Figure 6. Incidence rates of emergency department visits for compliant and noncompliant epileptic patients prescribed generic phenytoin or Dilantin® in 2013

Continuous variable data for medication possession revealed that a 1% positive
change in compliance resulted in a statistically significant 1% decrease in the number of
in-patient hospital admissions, OR = 0.99, 95% CI (0.98-0.99), p < 0.001. Additionally, a
10% positive change in compliance corresponded to a 12% decrease in in-patient
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hospitalization which was also statistically significant, OR = 0.88, 95% CI (0.86-0.90), p
< 0.001. Similarly, a 1% positive change in compliance resulted in a 2% decrease in
epilepsy related hospital admissions, OR = 0.98, 95% CI (0.98-0.98), p < 0.001. A 10%
positive change in compliance was related to a 16% decrease in epilepsy related
admissions, OR = 0.84, 95% CI (0.81-0.88), p < 0.001. Analyses of continuous outpatient
visit data indicated that a 1% positive change in compliance resulted in a statistically
significant 1% decrease in the number of outpatient visits (OR = 0.99, 95% CI [0.980.99], p < 0.001), while a 10% positive change in compliance resulted in a 13% decrease
in outpatient visits which was also statistically significant (OR = 0.87, 95% CI [0.850.89], p < 0.001). Data regarding the number of ED visits in epilepsy patients revealed
that a 1% positive change in compliance corresponded to a less than 1% decrease in the
number of ED visits, yet this change was statistically significant, OR = 1.00, 95% CI
(1.00-1.00), p < 0.001. A 10% positive change in compliance resulted in a statistically
significant 3% decrease in ED visits, OR = 0.97, 95% CI (0.96-0.97), p < 0.001. These
data, despite their significance, suggest that ED visits may be the least affected by
increased compliance.
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Discussion
This study was designed to provide an assessment of brand name Dilantin® and
generic phenytoin, comparing switch rates, compliance, and seizure related health
outcomes, as there is growing concern about the efficacy and safety of generic AED’s
(Haskins et. al, 2005). Health policy and managed care practices often focus on cost
containment and may encourage the use of generics because they are less expensive than
their branded counterparts. What may be greatly underestimated are the additional
unexpected costs associated with switching drugs and drug taking compliance, which can
cause both an increase in adverse events and increased medical use, such as
hospitalization and emergency room visits.
Results from this large managed care database demonstrated that patients treated
with phenytoin had a lower switch rate than those patients who started treatment on
Dilantin®. These initial results support existing evidence suggesting that patients who
begin treatment on a branded AED (i.e. Dilantin®) are more likely to switch treatment to
a generic. However, an unexpected finding in our study suggests that those who start
treatment on phenytoin and switch to Dilantin® are the least compliant compared to other
groups in our analyses. Study investigators initially hypothesized that switches to brand
name Dilantin® would prove better compliance outcomes, yet this switch showed the
opposite effect, a finding which is inconsistent with previous studies conducted in this
area. The greatest rates of compliance were evident in the Dilantin® treated patients who
experienced no switch, and therefore remained on the brand name drug during our one
year review period. A recent study by Gagne and colleagues (2015) showed differing
results with regard to brand/generic interchange. This group reported that adherence was
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better for generic AED’s than their branded versions, and that better medication
adherence was associated with better patient outcomes. Additionally, these authors noted
that generics were more effective than their brand name counterparts, further alluding to
the need for additional research in this area.
Additionally, the present study confirmed a relationship between brand or generic
AED compliance and inpatient hospital use, outpatient services, and ED visits. Noncompliant patients were significantly more likely to require in-patient services than
compliant patients, had greater than twice the risk of requiring outpatient services than
compliant patients, and were at a significantly greater risk for attending the ED than
compliant patients. These results are in line with previous research (Zachry et.al, 2009)
which provide further evidence that AED substitution may increase use of health care
services and strengthen the association between switching and adverse outcomes.
Furthermore, a systematic review of the current evidence on generic substitution of AEDs
(Yamada et al., 2011) including both retrospective and prospective controlled study
analyses of generic substitution of AEDs, found that the majority of retrospective studies
had indicated that generic AED substitution resulted in higher use of medical services in
patients with epilepsy. Our study, as well as those noted here, suggest that switching to
generic may be associated with increased rates of health services utilization and lower
medication possession ratios. It is important to ensure that patients, pharmacists,
prescribers and policy decision makers are aware of the potential risks.
Our analyses support existing concerns and challenges associated with AED
switching, for both patients and health care providers. Until formal guidelines are
administered by regulatory authorities, many epilepsy patients will continue to
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experience the negative effects of AED switching. It is clear from our literature review
that many physicians are concerned about the efficacy and safety associated with
unhampered substitution of generic AEDs, but may inaccurately underestimate how often
generic substitution occurs (Wilner, 2002). Policies that include mandatory substitution
or substitution without informed consent to both patient and provider are clearly
passionate topics and warrant further discussion (Maliepaard et al., 2009). Strong
recommendations regarding generic substitution from The Epilepsy Society and The
American Academy of Neurology as well as other advocacy and medical authorities
detail anecdotal evidence as well as clinical concerns regarding generic substitution.
Several states have issued laws regarding generic substitution, while other states are
considering implementation of similar legislation (Meyer et al., 2013). Supplementing the
existing body of knowledge, The Agency for Healthcare Research and Quality conducted
a comparative effectiveness review in December 2011, which evaluated the effectiveness
and safety of AEDs in patients with epilepsy. The review states that patients who initiate
treatment with and AED have no substantive differences in benefits or harms associated
with the use of generics versus brand name products (Talati et al., 2011). The review also
acknowledges that switching from a brand name AED to a generic AED may increase
health care utilization, but recognizes that “this is based on controlled observational study
data, which has inherent limitations substantially reducing the strength of evidence”
(Talati et al., 2011). These groups aim to scrutinize the need for continued robust studies
to evaluate generic AED substitution, and to directly examine the clinical effects of brand
to generic substitution in controlled trials.
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The results of this study provide additional substance and contributory evidence
to the area of research regarding epilepsy treatment, switching, and associated medical
events. Our study, however, does have its limitations. The first major limitation was the
use of observational data from a managed care database, and not utilizing a randomized
controlled trial design, which might have included additional patient data such as disease
characteristics, seizure frequency, disease duration or patients identified on multiple
AED’s. Our research falls short of specifically identifying whether generic AED’s
directly affect the risk of breakthrough seizures, however does include important results
regarding compliance and medical care use.
This study reinforces evidence showing that when an AED formulation switch
occurs, additional patient monitoring is necessary and patients should be considered
individually regarding the appropriateness for changes in treatment formulation. There
remain important considerations when substituting AED’s as compared to other chronic
or acute medications that need to be underscored. It is clear that further clinical studies
are needed to determine outcomes or possible pitfalls of generic substitution to guide
treatment decisions. Fortunately, there are a growing number of observational studies
comparing outcomes of patients with epilepsy being treated with brand name AEDs or
switched to generic to determine if there are differences in seizure control or seizurerelated adverse events. Unfortunately, however, the results of these studies are
conflicting, with some showing an increased risk of seizures and negative medical
outcomes when generic AED products were switched with brand name products (Zachry
et al., 2009) and other studies showing no difference in seizure control (Gagne et al.,
2015). More prospective studies analyzing the pharmacokinetics of brand to generic
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substitution are needed to assess the true variability of generic product use and switch. It
is important to ensure that every patient with epilepsy is receiving the best health care
possible, and thus prescribers and policy makers should be aware of the current state of
disease management including prescribing patterns of generic AEDs. When any
medication change occurs, physicians should consider intense monitoring of these
patients in the absence of conclusive data that support or challenge the utilization of
generic substitution (Kesselheim et al., 2015). Based on the current knowledge and
attitudes toward generic AED formulations, we conclude that both patients and
physicians need to advocate for education and policy that would help better inform and
enrich the medical community.
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